Fukayama S, Schipani E, Jüppner H, Lanske B, Kronenberg H M, Abou-Samra A B, Bringhurst F R
Endocrine Unit, Massachusetts General Hospital, Boston 02114.
Endocrinology. 1994 Apr;134(4):1851-8. doi: 10.1210/endo.134.4.8137752.
Homologous down-regulation of PTH/PTH-related peptide (PTHrP) receptor expression occurs in several PTH-responsive osteoblastic cell lines, but the mechanisms responsible are not well understood. We have used wild-type SaOS-2 human osteoblastic cells, in which homologous PTH/PTHrP receptor down-regulation occurs within 4 h, and a mutant cAMP-resistant subclone (Ca4A strain), to investigate the mechanisms by which PTH/PTHrP receptor mRNA is regulated. SaOS-2 cells expressed a single 2.2- to 2.5-kilobase transcript of PTH/PTHrP receptor mRNA, as assessed by Northern blot analysis of total RNA with a cDNA probe encoding the human PTH/PTHrP receptor. Homologous down-regulation of this PTH/PTHrP receptor mRNA first became significant when SaOS-2 cells had been treated with human (h) PTH-(1-34) (10(-7) M) for 8-12 h. By 24 h, steady state levels of PTH/PTHrP receptor mRNA were reduced by about 50%. This effect was mimicked by both (Bu)2cAMP (DBcAMP; 0.5 mM) and forskolin (Fsk; 10(-5) M). In contrast, down-regulation of PTH/PTHrP receptor mRNA by hPTH-(1-34), DBcAMP or Fsk was almost completely blocked in cAMP-resistant Ca4A cells. Short term (4-6 h) treatment with hPTH-(1-34), DBcAMP, or Fsk did not reduce steady state levels of PTH/PTHrP receptor mRNA in either SaOS-2 or Ca4A cells, although down-regulation was induced by 4-6 h of treatment with active phorbol esters such as 12-O-tetradecanoyl phorbol-13-acetate (200 nM) or phorbol-12,13-didecanoate (200 nM). Neither thapsigargin (1 microM) nor ionomycin (200 nM), both of which stimulate calcium transients in these cells, altered PTH/PTHrP receptor mRNA expression. Treatment with hPTH-(39-84) and hPTH-(53-84), which do not activate either cAMP-dependent protein kinase or protein kinase-C, but do stimulate 45Ca2+ uptake in these cells, did not alter PTH/PTHrP receptor mRNA expression. In the presence of actinomycin-D (1 microgram/ml), down-regulation of PTH/PTHrP receptor mRNA by hPTH-(1-34) was not observed. Cycloheximide (10 micrograms/ml) did not block down-regulation of PTH/PTHrP receptor mRNA induced by hPTH-(1-34). We conclude that homologous down-regulation of PTH/PTHrP receptor mRNA in SaOS-2 cells occurs later than the decline in functional surface receptors via a mechanism that does not involve enhanced mRNA degradation or new protein synthesis, but is dependent upon cAMP/cAMP-dependent protein kinase.
甲状旁腺激素/甲状旁腺激素相关肽(PTHrP)受体表达的同源性下调在几种对PTH有反应的成骨细胞系中都有发生,但其中的机制尚未完全清楚。我们使用野生型人成骨细胞系SaOS-2,其同源性PTH/PTHrP受体下调在4小时内发生,以及一个cAMP抗性突变亚克隆(Ca4A株),来研究PTH/PTHrP受体mRNA被调控的机制。通过用编码人PTH/PTHrP受体的cDNA探针,对总RNA进行Northern印迹分析,发现SaOS-2细胞表达单一的2.2至2.5千碱基的PTH/PTHrP受体mRNA转录本。当用人类(h)PTH-(1-34)(10^(-7) M)处理SaOS-2细胞8至12小时时,这种PTH/PTHrP受体mRNA的同源性下调开始变得显著。到24小时时,PTH/PTHrP受体mRNA的稳态水平降低了约50%。这种效应被二丁酰环磷腺苷(DBcAMP;0.5 mM)和福斯可林(Fsk;10^(-5) M)模拟。相反,hPTH-(1-34)、DBcAMP或Fsk对PTH/PTHrP受体mRNA的下调在cAMP抗性Ca4A细胞中几乎完全被阻断。用hPTH-(1-34)、DBcAMP或Fsk进行短期(4至6小时)处理,在SaOS-2或Ca4A细胞中均未降低PTH/PTHrP受体mRNA的稳态水平,尽管用活性佛波酯如12-O-十四烷酰佛波醇-13-乙酸酯(200 nM)或佛波醇-12,13-十二烷酸酯(200 nM)处理4至6小时可诱导下调。毒胡萝卜素(1 microM)和离子霉素(200 nM),这两种物质均可刺激这些细胞中的钙瞬变,但均未改变PTH/PTHrP受体mRNA的表达。用hPTH-(39-84)和hPTH-(53-84)处理,它们既不激活cAMP依赖性蛋白激酶也不激活蛋白激酶-C,但可刺激这些细胞中的45Ca2+摄取,也未改变PTH/PTHrP受体mRNA的表达。在放线菌素-D(1微克/毫升)存在的情况下,未观察到hPTH-(1-34)对PTH/PTHrP受体mRNA的下调。环己酰亚胺(10微克/毫升)未阻断hPTH-(1-34)诱导的PTH/PTHrP受体mRNA的下调。我们得出结论,SaOS-2细胞中PTH/PTHrP受体mRNA的同源性下调发生时间晚于功能性表面受体的减少,其机制不涉及mRNA降解增强或新蛋白质合成,但依赖于cAMP/cAMP依赖性蛋白激酶。